Clinical Translational Research of Stem Cell Therapy for Diabetes Won National Key Project

Source: Medical Network

Medical Network News, October 27th, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Xijing Hospital Affiliated to Military Medical University of the Chinese People’s Liberation Army Air Force, and Beijing Jiyuan Biotechnology Co., Ltd. jointly applied for the 2020 national key research and development plan "Stem Cell and Transformation Research" The special, human GLP-1 and FGF21 dual-factor high-expressing autologous adipose-derived mesenchymal stem cell transfusion for the treatment of type 2 diabetes clinical research was approved by the Ministry of Science and Technology in October. The approved project is the "Clinical Study of Human GLP-1 and FGF21 Dual Factor High-Expression Autologous Adipose Mesenchymal Stem Cells Transfusion in the Treatment of Type 2 Diabetes", which is the first diabetes study since the approval of the key project of "Stem Cell and Translational Research" in 2016 Clinical research is the highest level national project in the field of stem cell and translational research in my country.

The lead unit is Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Xijing Hospital Affiliated to Military Medical University of Chinese People's Liberation Army Air Force and Beijing Jiyuan Biotechnology Co., Ltd. jointly complete the research and development of the project.

The project leader Professor Cao Yanan from Shanghai Ruijin Hospital emphasized that the overall goal of the research project is to further enhance the overall strength of stem cell clinical translational research, establish a standardized, high-efficiency and high-quality operation mode, and use clinical potential and vitality in the practice of clinical and basic research. Continuously enrich and improve the scientific nature of the results to better serve diabetic patients. Ruijin Hospital Affiliated to Jiaotong University is the National Clinical Medical Research Center for Metabolic Diseases, among which the National Hospital of Endocrinology and Metabolism has ranked first for nine consecutive years. Professor Yanan Cao said: Establish a specific scientific implementation plan for the subject, clarify the requirements, and the subject team will hold regular subject implementation promotion meetings. Through the close cooperation of all parties, we will build a high-efficiency new drug clinical research technology service platform, especially in the early clinical research of biological cell innovative drugs and the effectiveness and safety evaluation of innovative drugs. It has played a role in modifying stem cells for clinical transformation of metabolic diseases in China. Leading and demonstrating role.

It is understood that the prevalence of diabetes in my country is also showing a rapid growth trend. In 2017, there were 114.4 million diabetic patients in China between 20 and 79 years old, ranking first in the world. Type 2 diabetes as a metabolic disease has been included in the national major chronic disease management and treatment plan. After years of basic research, Beijing Jiyuansheng Technology Co., Ltd. has made a major breakthrough in the treatment of type 2 diabetes by using "human GLP-1 and FGF21 dual-factor high expression autologous adipose-derived mesenchymal stem cells to treat type 2 diabetes." patent. At the same time, it applied for international patents such as the United States. The research project has passed the safety evaluation of stem cell clinical research records and has begun to enter preclinical research and initiate the IND application process.